Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds |
| OF THE INVENTION The present invention thus provides as a novel compound the R(+)-enantiomer of N-... |
|
L-DOPA ethyl ester to treat Parkinson's disease |
| OF THE INVENTION This invention provides a composition which comprises a pharmaceutically ... |
|
Episomal vector systems and related methods |
| The present invention provides papilloma virus episomal vector systems and methods for papilloma ... |
|
Method for treating Parkinson's disease employing an ATP-sensitive potassium channel blocker |
| What is claimed is: 1. A method for treating Parkinson's disease, which comprises administering ... |
|
Method of treatment of parkinson's disease |
| We claim: 1. A method of treatment of Parkinson's disease in a patient in need of such treatment, ... |
|
4-aminoethoxy indolone derivatives |
| What is claimed is: 1. A compound of the formula I: ##STR5## in which: Y is hydrogen, halogen or ... |
|
Genetically engineered cells that produce produce L. Dopa |
| In one aspect, the present invention provides a process of increasing the production of dopamine in ... |
|
C. elegans deletion mutants |
| What is claimed is: 1. A nematode having null mutations in hop-1 and sel-12, said nematode having a ... |
|
Feline hepatocyte growth factor |
| The invention claimed is: 1. An isolated DNA or RNA encoding a protein having an amino acid ... |
|
ppRB.sup.110 -phosphoprotein the retinoblastoma susceptibility gene product |
| OF FIGURES FIG. 1 is the chromatogram illustrating the identification of RB proteins by ... |
|
|
Biodegradable high molecular weight polymeric linkers and their conjugates
| Details |
Inventors: Greenwald, Richard B.; Martinez, Anthony J.; Choe, Yun H.; Pendri, Annapurna;
Assignee: Enzon, Inc. (Piscataway, NJ)
Primary Examiner: Low; Christopher S. F.
Assistant Examiner: Lukton; David
Attorney, Agent or Firm: Roberts & Mercanti, LLP
Polymeric compounds of the formula: (D).sub.n --M--(R.sub.1).sub.m (I) wherein (m) and (n) independently selected positive integers, preferably from about 1 to about 6 each; D is a residue of a biologically active moiety; M is a multifunctional linker/spacer moiety; and R.sub.1 is a polymer residue are disclosed. Methods of preparing the same and methods of treatment using the same are also included as part of the present invention. |
|
DETAILED DESCRIPTION The present invention includes compounds of the formula: (D). sub. n --M--(R. sub. 1). sub. m (I) wherein (m) and (n) independently selected positive integers, preferably from about 1 to about 6 each; D is a residue of a biologically active moiety: M is a multifunctional linker/spacer moiety; and R. sub. 1 is a polymer residue. Methods of preparing the same and methods of treatment using the same are also included as part of the present invention. With respect to the linking of the polymer strands, the artisan is provided with higher total molecular weight polymers which are useful in providing therapeutic conjugates with relatively long T. sub. 1/2 's. There are several advantages associated with these types of polymers. For example, depending upon the linkages used to attach the polymer strands to the multifunctional spacer groups, the artisan can design relatively high molecular weight polymeric transport systems which will predictably biodegrade into polymers of relatively low molecular weight which are more readily eliminated from the body than the singular polymer of higher molecular weight. Secondly, because relatively small molecular weight polymers are used to build the biodegradable transport form, the polydispersity associated with some single strand high moleulcar weight polymers such as when PEG has a molecular weight of over 40 kDa is substantially avoided. Additional advantages associated with using the multifunctional spacers in the polymers of the present invention is that there is a large number of multifunctional moieties readily available. Thus, the artisan can prepare polymeric prodrug systems having high degrees of loading, i. e. 3-6 or more molecules of active drug per transport system. A still further advantage of the multifunctional spacers of polymeric systems of the present invention is that the artisan can form prodrugs of almost any therapeutic molecule. For example, the multifunctional spacer can be designed to include the capability of accommodating a linker for attaching to hydroxyl residues, amine residues, sulfhydryl residues, etc
|
| Related patents |
|
|
Modified polypeptides with high activity and reduced allergenicity
OF THE INVENTION The modified polypeptide of the present invention is represented by the formula: A-B.sub.n containing, as essential components, a enzyme, A, and a ...
|
|
|
Poly(ethylene glycol) derivatives with proximal reactive groups
OF THE INVENTION The terms "group," "functional group," "moiety," "active moiety," "reactive site," reactive group" and "reactive moiety" are used in the art and herein ...
|
|
|
Devices for cloaking transplanted cells
A variety of devices can be used to contain or cloak a source of a therapeutic substance, often cells, which source provides the substance to a host or recipient subject....
|
|
|
Terminally-branched polymeric linkers and polymeric conjugates containing the same
In one aspect of the invention, compounds of Formula (I) are provided: ##STR6## wherein: J is ##STR7## E.sub.1-4 are independently selected from the group consisting of ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising rectally administering to a patient a ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising a therapeutically effective dosage amount of an ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A pharmaceutical composition for enhancing rectal absorption of L-dopa by administering a formulation comprising a therapeutically effective ...
|
|
|
Method to treat Parkinsons disease
I claim: 1. The method of treatment of Parkinson's disease and related neurological syndromes which consists of administering by the oral or sublingual route to a ...
|
|
|
Method of using cytoprotective alcohols to treat neural disease and neural injury
The present invention is grounded in the surprising discovery that hexacosanol and analogues and homologs thereof, including saturated and unsaturated straight chain ...
|
|
|
Methods of treating Parkinson's disease using melanin
OF THE INVENTION One aspect of the present invention relates to the treatment of a mammal having a disease of a tissue which exhibits a melanin deficiency by the ...
|
|
|